ALMS NASDAQ
Credit Risk of going bust: higher than 83% of companies Debt: 4.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99%), Alumis Inc. would be worth roughly what it owes.
Total debt $36.4M against a stock market value of $859.4M.
Distance to default 2.38 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.2M (short-term plus half of long-term), stock volatility 132.1%; Altman Z'' -2.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | S-Sale | 48,066 | $10.55 | 2026-09-08 |
| AKKARAJU SRINIVAS | S-Sale | 48,065 | $10.55 | 2026-09-08 |
| AKKARAJU SRINIVAS | P-Purchase | 273,291 | $10.63 | 2026-09-08 |
| AKKARAJU SRINIVAS | P-Purchase | 273,290 | $10.63 | 2026-09-08 |
| AKKARAJU SRINIVAS | P-Purchase | 220,070 | $11.17 | 2026-09-04 |